Cadila Healthcare Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus seeks DCGI approval to undertake clinical trials for monoclonal antibodies cocktail that can neutralise COVID infection27-05-2021
27-05-2021
CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus seeks DCGI approval to undertake clinical trials for monoclonal antibodies cocktail that can neutralise COVID infection27-05-2021
CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus and TLC sign agreement to market Liposomal Amphotericin B, a critical drug to treat Black Fungus or Mucormycosis in India26-05-2021
Cadila to produce up to 30 mn Covid-19 vaccine doses a month
Vaccine meant to be given in three doses25-05-2021
CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Update on Analyst Call24-05-2021
Cadila Healthcare Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus launches Ujvira (Trastuzumab Emtansine), a breakthrough in Breast Cancer treatment24-05-2021
Cadila Healthcare Ltd - 532321 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper cutting dated May 22, 2021 with regard to Notice of Board Meeting of the Company scheduled to be held on Thursday, May 27, 2021 published in the Financial Express- English and Gujarati Editions22-05-2021
CADILA HEALTHCARE LTD. - 532321 - Board to consider FY21 results & Final Dividend on May 27, 2021
Further to the earlier letter dated March 25, 2021, Cadila Healthcare Ltd has informed BSE that the meeting of the Board of Directors of the Company will be held on May 27, 2021 to consider apart from other agenda items to approve the audited financial results for the quarter / year ended on March 31, 2021 and to recommend final dividend for the financial year ended on March 31, 2021.The trading window as per the SEBI Insider Trading Regulations, shall remain closed till May 30, 2021 and shall open for trading on and from May 31, 2021 for all the Directors and Designated Persons.21-05-2021